Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study

IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).

(2021) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Hepatocellular carcinoma in non-alcoholic fatty liver disease—a review of an emerging challenge facing clinicians

(2021) Daniel Geh et al.   Hepatobiliary Surgery and Nutrition

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

(2021) Dominik Pfister et al.   NATURE

Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH

(2021) Michael Dudek et al.   NATURE

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD−1/PD-L1 Checkpoint Blockade

(2020) Tomoko Aoki et al.   Cancers

Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease

(2019) Ankur Srivastava et al.   JOURNAL OF HEPATOLOGY

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET

Hepatocellular carcinoma

(2018) Alejandro Forner et al.   LANCET

Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis

(2018) Atsushi Hiraoka et al.   Liver Cancer

A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update

(2018) Ryosuke Tateishi et al.   JOURNAL OF GASTROENTEROLOGY

Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies

(2017) Jordi Bruix et al.   JOURNAL OF HEPATOLOGY

Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function

(2017) Atsushi Hiraoka et al.   Liver Cancer

Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications

(2017) Atsushi Hiraoka et al.   Liver Cancer

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

(2016) Zobair M. Younossi et al.   HEPATOLOGY

Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma

(2016) Atsushi Hiraoka et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States

(2015) Robert J. Wong et al.   GASTROENTEROLOGY

Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade

(2015) Philip J. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease

(2015)   JOURNAL OF HEPATOLOGY

Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study

(2014) Ryosuke Tateishi et al.   JOURNAL OF GASTROENTEROLOGY

Epidemiology of Hepatocellular Carcinoma

(2013) Sahil Mittal et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics

(2012) Y Kanda   BONE MARROW TRANSPLANTATION

The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology

(2012) Naga Chalasani et al.   GASTROENTEROLOGY

New contrast enhanced ultrasonography agent: Impact of Sonazoid on radiofrequency ablation

(2011) Atsushi Hiraoka et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Imaging Study of Early Hepatocellular Carcinoma: Usefulness of Gadoxetic Acid–enhanced MR Imaging

(2011) Katsuhiro Sano et al.   RADIOLOGY

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma

(2010) Amelia J. Hessheimer et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Intraindividual Comparison of Gadoxetate Disodium–enhanced MR Imaging and 64-Section Multidetector CT in the Detection of Hepatocellular Carcinoma in Patients with Cirrhosis

(2010) Michele Di Martino et al.   RADIOLOGY

Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

(2010) Riccardo Lencioni et al.   SEMINARS IN LIVER DISEASE

Clinical translation in the treatment of hepatocellular carcinoma following the introduction of contrast-enhanced ultrasonography with Sonazoid

(2009) ATSUSHI HIRAOKA et al.   Oncology Letters

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE